BACKGROUND: Relatively little attention has been given to the epidemiology and management of cancer of the ampulla of Vater. SETTING: A series of 111 patients with a cancer of the ampulla of Vater diagnosed over a 20-year period (1976-1995) in a well-defined French population was used to analyse its incidence, management and prognosis as well as to determine time trends. Prognosis was determined by using crude and relative survival rates. Factors predictive of survival were also identified using a relative survival model in a multivariate analysis. RESULTS: Age-standardized incidence rates were 3.8 per 1000000 inhabitants in men and 2.7 per 1000000 inhabitants in women. Incidence increased over time in men from 1.9 during the first period (1976-1980) to 5.9 during the last period (1991-1995). In women, incidence rates remained stable. A resection for cure was performed in 52 cases (48.1%). Overall, 9.9% of these cancers were classified TNM stage I and 54.1% stage IV. There was no significant variation in treatment modalities and in stage at diagnosis over the study period. The overall operative mortality rate was 7.5%. Relative survival rates were 58.9% at 1 year, 30.9% at 3 years and 20.9% at 5 years. Five-year relative survival rates varied from 72.8% in TNM stage I cancers to 6.6% in TNM stage IV cancers. Age, treatment procedure and stage at diagnosis significantly influenced the prognosis of cancer of the ampulla of Vater. In a multivariate analysis, stage at diagnosis remained the major prognostic factor (P<0.01). CONCLUSIONS: Although its incidence is increasing in men, cancer of the ampulla of Vater remains a rare tumour in both sexes. No improvements in the management and care of patients have been achieved. Further studies are needed to enhance the understanding of this cancer.
BACKGROUND: Relatively little attention has been given to the epidemiology and management of cancer of the ampulla of Vater. SETTING: A series of 111 patients with a cancer of the ampulla of Vater diagnosed over a 20-year period (1976-1995) in a well-defined French population was used to analyse its incidence, management and prognosis as well as to determine time trends. Prognosis was determined by using crude and relative survival rates. Factors predictive of survival were also identified using a relative survival model in a multivariate analysis. RESULTS: Age-standardized incidence rates were 3.8 per 1000000 inhabitants in men and 2.7 per 1000000 inhabitants in women. Incidence increased over time in men from 1.9 during the first period (1976-1980) to 5.9 during the last period (1991-1995). In women, incidence rates remained stable. A resection for cure was performed in 52 cases (48.1%). Overall, 9.9% of these cancers were classified TNM stage I and 54.1% stage IV. There was no significant variation in treatment modalities and in stage at diagnosis over the study period. The overall operative mortality rate was 7.5%. Relative survival rates were 58.9% at 1 year, 30.9% at 3 years and 20.9% at 5 years. Five-year relative survival rates varied from 72.8% in TNM stage I cancers to 6.6% in TNM stage IV cancers. Age, treatment procedure and stage at diagnosis significantly influenced the prognosis of cancer of the ampulla of Vater. In a multivariate analysis, stage at diagnosis remained the major prognostic factor (P<0.01). CONCLUSIONS: Although its incidence is increasing in men, cancer of the ampulla of Vater remains a rare tumour in both sexes. No improvements in the management and care of patients have been achieved. Further studies are needed to enhance the understanding of this cancer.
Authors: Brandon C Chapman; Ana Gleisner; Irada Ibrahim-Zada; Douglas M Overbey; Alessandro Paniccia; Cheryl Meguid; Brian Brauer; Csaba Gajdos; Martin D McCarter; Richard D Schulick; Barish H Edil Journal: Surg Endosc Date: 2017-08-04 Impact factor: 4.584
Authors: Winston Wong; Maeve A Lowery; Michael F Berger; Yelena Kemel; Barry Taylor; Ahmet Zehir; Preethi Srinivasan; Chaitanya Bandlamudi; Joanne Chou; Marinela Capanu; Anna Varghese; Kenneth H Yu; Christine A Iacobuzio-Donahue; Jinru Shia; David S Klimstra; William R Jarnagin; Zsofia K Stadler; Eileen M O'Reilly Journal: Cancer Date: 2019-01-08 Impact factor: 6.860
Authors: Chandana Javvaji; Jacob R Bledsoe; Lloyd Hutchinson; Ediz F Cosar; Lacey J McIntosh; Venu G Bathini Journal: J Gastrointest Cancer Date: 2020-03
Authors: Andrea Di Giorgio; Sergio Alfieri; Fabio Rotondi; Francesco Prete; Dario Di Miceli; Marco Pericoli Ridolfini; Fausto Rosa; Marcello Covino; Giovanni Battista Doglietto Journal: World J Surg Date: 2005-04 Impact factor: 3.352
Authors: Brett L Ecker; Charles M Vollmer; Stephen W Behrman; Valentina Allegrini; John Aversa; Chad G Ball; Courtney E Barrows; Adam C Berger; Martha N Cagigas; John D Christein; Elijah Dixon; William E Fisher; Mollie Freedman-Weiss; Francisco Guzman-Pruneda; Robert H Hollis; Michael G House; Tara S Kent; Stacy J Kowalsky; Giuseppe Malleo; Ronald R Salem; Roberto Salvia; Carl R Schmidt; Thomas F Seykora; Richard Zheng; Amer H Zureikat; Paxton V Dickson Journal: JAMA Surg Date: 2019-08-01 Impact factor: 14.766
Authors: D Santini; G Tonini; F M Vecchio; D Borzomati; B Vincenzi; S Valeri; A Antinori; F Castri; R Coppola; P Magistrelli; G Nuzzo; A Picciocchi Journal: J Clin Pathol Date: 2005-02 Impact factor: 3.411
Authors: Jordan M Winter; John L Cameron; Kelly Olino; Joseph M Herman; Mechteld C de Jong; Ralph H Hruban; Christopher L Wolfgang; Frederic Eckhauser; Barish H Edil; Michael A Choti; Richard D Schulick; Timothy M Pawlik Journal: J Gastrointest Surg Date: 2010-02 Impact factor: 3.452
Authors: Ibrahim Nassour; Ali A Mokdad; Rebecca M Minter; Patricio M Polanco; Mathew M Augustine; John C Mansour; Matthew R Porembka; Sam C Wang Journal: J Surg Oncol Date: 2017-10-02 Impact factor: 3.454